A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma
Latest Information Update: 16 Aug 2019
At a glance
- Drugs Sorafenib (Primary)
- Indications Adenoid cystic carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- 16 Aug 2019 Status changed from recruiting to completed.
- 06 Jul 2011 New trial record